Spear Bio
NAB-Sure ™, the new cell-free SARS-CoV-2 neutralizing antibody assay will be featured at Vaccine Summit in Washington D.C. PRESS RELEASE Woburn, MA, October 11 2022 – Feng Xuan, Spear Bio’s Co-Founder and chief technology officer, will share insightful research and results featuring NAB-Sure™ – a new, ultrasensitive immunoassay – during the Vaccine Summit 2022. His presentation […]
Spear Bio Recognized by AACC for “Best Abstract in Metabolomics” Poster PRESS RELEASE Woburn, MA, August 31, 2022 – Developer of ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its breakthrough immunoassay technology at the recent American Association of Clinical Chemistry’s scientific meeting and clinical lab expo, held in Chicago. At the AACC event Spear […]
Wyss Institute at Harvard University launches SPEAR Bio to empower disease research, patient care, and drug development with its small-sample, ultrasensitive, protein-detection technology. Spear Bio is working towards commercializing its first assay, which accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples. PRESS RELEASE By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for […]
New Neutralizing Antibody Test Kit Has High Sensitivity and Ability to Analyze Micro-Samples PRESS RELEASE Woburn, MA, August 22, 2022 – Pharmaceutical drug developers and healthcare researchers need innovative tools to understand COVID-19 immune response and validate vaccines and therapeutics critical to managing the pandemic. The newest development in assay technology, the NAB-Sure™ SARS-CoV-2 Neutralizing […]